Keck Medicine of USC has launched a Phase 2 clinical trial investigating the effectiveness of a new outpatient, nonsurgical endoscopic procedure in stabilizing blood glucose levels for patients.
The procedure is designed for patients before they require insulin. It targets the duodenum (the first part of the small intestine), which works with the pancreas to regulate insulin and blood glucose levels. Patients are typically able to resume normal activities a few days later.
More than 37 million Americans have diabetes, and approximately 90-95% have Type 2 diabetes. According to the Centers for Disease Control and Prevention, serious potential complications include heart disease and stroke, kidney disease, nerve damage, compromised oral health, vision loss and hearing loss.
To read the full story, click here.